Selective blockade of microRNA-31-5p−calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia burden
10 affiliations
- 1Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, John Radcliffe Hospital, Oxford, UK
- 2Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX USA
- 3Department of Integrative Physiology, Baylor College of Medicine, Houston, TX USA
- 4Department of Pharmacology and Physiology, Faculty of Medicine and Research Centre, Montreal Heart Institute and University of Montreal, Montreal, Quebec Canada
- 5Cardiothoracic Surgery, Oxford Heart Centre, John Radcliffe Hospital, Oxford, UK
- 6Clinical Neurology, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
- 7School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK
- 8Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec Canada
- 9Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany
- 10IHU LIRYC and Fondation Bordeaux Université, Bordeaux, France
Abstract
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is promoted by atrial fibrosis, a form of structural remodelling for which effective therapies are lacking. MicroRNA-31-5p (miR-31-5p), an aging-associated, atrial-enriched microRNA, has been linked to AF, but its role in atrial fibrosis is unknown. Here we show that atrial fibroblasts from patients with persistent AF exhibit increased miR-31-5p expression and reduced expression of the calcitonin receptor (CTR, encoded by CALCR). MiR-31-5p directly represses CTR and promotes pro-fibrotic fibroblast responses, whereas its inhibition restores CTR expression. Fibroblast-specific overexpression of miR-31 in mice reduces atrial CTR expression, increases atrial fibrosis and enhances arrhythmia susceptibility. Selective disruption of miR-31-5p−CALCR binding using a locked nucleic acid target site blocker restores atrial CTR expression, prevents fibrosis progression and reduces arrhythmia burden. In mice with established atrial remodeling, this strategy promotes fibrosis regression, identifying the miR-31-5p−CTR axis as a potential therapeutic target in AF.
Related
- The use of triptans, opioids, and other rescue medications among patients with migraine prescribed calcitonin gene–related peptide inhibitors for migraine prophylaxis
- Selective serotonin reuptake inhibitors and immune checkpoint blockade in solid tumors: A target trial emulation with pan-cancer transcriptomic analyses
- Current Evidence on the Use of Calcitonin Gene-Related Peptide-Targeting Therapies in Children and Adolescents.
- Potential drug-drug interaction risks of selective serotonin reuptake inhibitors in outpatients: a retrospective analysis using two screening databases
- Primary Small Cell Carcinoma of the Thyroid With Absent Calcitonin Expression: A Diagnostic Challenge
BibTeX
@article{trompf2026selective,
title = {{Selective blockade of microRNA-31-5p−calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia burden}},
author = {Jasha Trompf and Kathryn Cox and Mohit Hulsurkar and Lucia M. Moreira and Chi Him Kendrick Yiu and Aaron M. Johnston and Satadru K. Lahiri and Shuai Zhao and Paul Robinson and Roddy Hiram and Mozhdeh Mehdizadeh and Lorena Perez Carrillo and Rana Sayeed and George Krasopoulos and Vivek Srivastava and Nicholas Walcot and Shakil Farid and Antonios Kourliouros and Priya Sastry and David A. Menassa and Benjamin Davies and Rita A. Schack and Robia G. Pautler and Keith M. Channon and Craig Lygate and Stanley Nattel and Xander H. T. Wehrens and Svetlana Reilly},
journal = {Nature Cardiovascular Research},
year = {2026},
month = oct,
doi = {10.1038/s44161-026-00897-1},
url = {https://doi.org/10.1038/s44161-026-00897-1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Selective blockade of microRNA-31-5p−calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia burden
AU - Jasha Trompf
AU - Kathryn Cox
AU - Mohit Hulsurkar
AU - Lucia M. Moreira
AU - Chi Him Kendrick Yiu
AU - Aaron M. Johnston
AU - Satadru K. Lahiri
AU - Shuai Zhao
AU - Paul Robinson
AU - Roddy Hiram
AU - Mozhdeh Mehdizadeh
AU - Lorena Perez Carrillo
AU - Rana Sayeed
AU - George Krasopoulos
AU - Vivek Srivastava
AU - Nicholas Walcot
AU - Shakil Farid
AU - Antonios Kourliouros
AU - Priya Sastry
AU - David A. Menassa
AU - Benjamin Davies
AU - Rita A. Schack
AU - Robia G. Pautler
AU - Keith M. Channon
AU - Craig Lygate
AU - Stanley Nattel
AU - Xander H. T. Wehrens
AU - Svetlana Reilly
PY - 2026
DA - 2026/10/30
JO - Nature Cardiovascular Research
DO - 10.1038/s44161-026-00897-1
UR - https://doi.org/10.1038/s44161-026-00897-1
AB - Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is promoted by atrial fibrosis, a form of structural remodelling for which effective therapies are lacking. MicroRNA-31-5p (miR-31-5p), an aging-associated, atrial-enriched microRNA, has been linked to AF, but its role in atrial fibrosis is unknown. Here we show that atrial fibroblasts from patients with persistent AF exhibit increased miR-31-5p expression and reduced expression of the calcitonin receptor (CTR, encoded by CALCR). MiR-31-5p directly represses CTR and promotes pro-fibrotic fibroblast responses, whereas its inhibition restores CTR expression. Fibroblast-specific overexpression of miR-31 in mice reduces atrial CTR expression, increases atrial fibrosis and enhances arrhythmia susceptibility. Selective disruption of miR-31-5p−CALCR binding using a locked nucleic acid target site blocker restores atrial CTR expression, prevents fibrosis progression and reduces arrhythmia burden. In mice with established atrial remodeling, this strategy promotes fibrosis regression, identifying the miR-31-5p−CTR axis as a potential therapeutic target in AF.
SN - 2731-0590
ER -